Indication: Philadelphia Chromosome Ph+ALL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.
Sub-indication: Philadelphia Chromosome Ph+ALL
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Children's Oncology Group (COG)
Learn more at ClinicalTrials.gov
Email for more information: NCRI-Cancer@NortonHealthcare.org
